All In Biotech

Drug Trial Radar · NCT00230971

Study Comparing Tigecycline Versus Ceftriaxone Sodium Plus Metronidazole in Complicated Intra-abdominal Infection (cIAI)

A Multicenter, Open-Label, Randomized Comparative Study of Tigecycline vs Ceftriaxone Sodium Plus Metronidazole for the Treatment of Hospitalized Subjects With Complicated Intra-abdominal Infection

Last checked: Nov 19, 2026Latest source record: Feb 25, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 473 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

473

Actual

Start

Oct 2005

Primary completion

Sep 2008

Study completion Sep 2008

Sponsor

Sponsor type
Industry
First posted
Oct 3, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study of the safety and efficacy of tigecycline to ceftriaxone sodium plus metronidazole in hospitalized subjects with cIAI. Subjects will be followed for efficacy through the test-of-cure assessment. Safety evaluations will occur through the treatment and post-treatment periods and continue through resolution or stability of the adverse event(s).

Conditions

  • Appendicitis
  • Cholecystitis
  • Diverticulitis
  • Intra-Abdominal Abscess
  • Intra-Abdominal Infection
  • Peritonitis

Interventions

  • tigecyclineDrug

    every 12 hours IV (an initial dose of 100 mg followed by 50 mg every 12 hours)

  • ceftriaxone plus metronidazoleDrug

    Ceftriaxone sodium 2 g once daily intravenously plus metronidazole 1 g to 2 g daily given in divided doses intravenously. Test article should be administered for a minimum of 4 days and up to 14 days at the discretion of the investigator.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Clinically Evaluable (CE) Patients With Clinical Response of Cure at the Test-of-Cure (TOC) VisitTime frame: up to 6 weeks

Locations

68 sites in 19 countries. Site status is shown where the registry gives one.

  • Site not named

    Cairns, Australia

  • Site not named

    Parkville, Australia

  • Site not named

    Nambour, Queensland, Australia

  • Site not named

    Shanghai, China

  • Site not named

    Odense, Denmark

  • Site not named

    Lahti, Finland

  • Site not named

    Seinäjoki, Finland

  • Site not named

    Tampere, Finland

  • Site not named

    Marseille, France

  • Site not named

    Nîmes, France

  • Site not named

    Pierre-Bénite, France

  • Site not named

    Saint-Denis, France

  • Site not named

    Bochum, Germany

  • Site not named

    Frankfurt, Germany

  • Site not named

    Freiburg im Breisgau, Germany

  • Site not named

    Heidelberg, Germany

  • Site not named

    Leipzig, Germany

  • Site not named

    Lübeck, Germany

  • Site not named

    Münster, Germany

  • Site not named

    Tübingen, Germany

  • Site not named

    Athens, Greece

  • Site not named

    Athens, Greece

  • Site not named

    Thessaloniki, Greece

  • Site not named

    New Territories, Hong Kong

  • Site not named

    Pokfulam, Hong Kong

  • Site not named

    Bhopal, India

  • Site not named

    Lucknow, India

  • Site not named

    Mumbai, India

  • Site not named

    New Delhi, India

  • Site not named

    Hyderabad, Telangana, India

  • Site not named

    Brescia, Italy

  • Site not named

    Genova, Italy

  • Site not named

    Pavia, Italy

  • Site not named

    Rome, Italy

  • Site not named

    Udine, Italy

  • Site not named

    Vicenza, Italy

  • Site not named

    Manila, Philippines

  • Site not named

    Quezon City, Philippines

  • Site not named

    Quezon City, Philippines

  • Site not named

    Almada, Portugal

Showing 40 of 68 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.